Lexaria Bioscience - Warrants (11/01/2026) Return on Equity

Lexaria Bioscience - Warrants (11/01/2026) (LEXXW) currently reports a ROE of -163.18%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Lexaria Bioscience - Warrants (11/01/2026)'s ROE history and peer comparisons.

Lexaria Bioscience - Warrants (11/01/2026)'s ROE of -163.18% is lower than the Healthcare sector average of 22.76%. That is roughly 816.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Lexaria Bioscience - Warrants (11/01/2026)'s current -163.18% should be judged against Healthcare norms (sector average: 22.76%) and against LEXXW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -163.18%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Lexaria Bioscience - Warrants (11/01/2026), and consider following LEXXW for alerts when major investors trade the stock.

Lexaria Bioscience - Warrants (11/01/2026) is classified in the Healthcare sector. On ROE, it currently shows -163.18% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LEXXW with unrelated industries.